Clinical Trial

Dose Finding Trial of R21/Matrix-M in School Children

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is a double-blind, randomised, trial recruiting participants from the R21 phase IIb trial (VAC 076) which took place between May 2019 and July 2023 in Nanoro, Burkina Faso. Participants (n=30-40) who have previously received four doses of the 5µg R21/50µg Matrix-M malaria vaccine in VAC 076 will be randomised to receive either 5µg R21/50µg Matrix-M or 10µg R21/50µg Matrix-M. Safety and immunogenicity of a booster at school age at these two different doses will be assessed. Participants will be followed up for one year after the booster.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-16.
Status change: Not Yet Recruiting → Recruiting 2026-02-19
Trial Details
NCT Number NCT07074665
Lead Sponsor University of Oxford
Collaborators: Institut de Recherche en Sciences de la Sante, Burkina Faso
Conditions Malaria (Plasmodium Falciparum)
Enrollment 40 participants
Start Date 2026-02-18
Primary Completion 2026-04 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-23